Memantine improves safety of thrombolysis for stroke

Stroke

Volumn 43, Issue 10, 2012, Pages 2774-2781

  Montagne, Axel ^a   Hébert, Marie ^a   Jullienne, Amandine ^a   Lesept, Flavie ^a   Le Béhot, Audrey ^a   Louessard, Morgane ^a   Gauberti, Maxime ^a   Orset, Cyrille ^a   Ali, Carine ^a   Agin, Véronique ^a   Maubert, Eric ^a   Vivien, Denis ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

glutamatergic transmission; ischemic hemorrhagic strokes; memantine; rtPA; sensorimotor functions; thrombolysis

Indexed keywords

ALTEPLASE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMATED GAIT ANALYSIS; BLOOD CLOT LYSIS; BRAIN CELL; BRAIN HEMORRHAGE; CALCIUM VIDEOMICROSCOPY; CONTROLLED STUDY; DRUG SAFETY; EMBRYO; GAIT; IN VITRO STUDY; MICROSCOPY; MOUSE; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STRING SIGN; STROKE;

ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; CHEMOTHERAPY, ADJUVANT; EXCITATORY AMINO ACID ANTAGONISTS; FIBRINOLYTIC AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MEMANTINE; MICE; MODELS, ANIMAL; N-METHYLASPARTATE; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84866733927     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.669374     Document Type: Article

References (37)

1. NINDS Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7:59-64.
4. Strbian D, Meretoja A, Putaala J, Kaste M, Tatlisumak T. Cerebral edema in acute ischemic stroke patients treated with intravenous thrombolysis. Int J Stroke. 2012;1747-4949.
5. Vivien D, Gauberti M, Montagne A, Defer G, Touzé E. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab. 2011;31:2119-2134.
6. Benchenane K, Berezowski V, Ali C, Fernández-Monreal M, López-Atalaya JP, Brillault J, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation. 2005;111:2241-2249. (Pubitemid 40632441)
7. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 2009;32:48-55.
8. Suzuki Y. Role of tissue-type plasminogen activator in ischemic stroke. J Pharmacol Sci. 2010;113:203-207.
9. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008;14: 731-737.
10. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron. 2006;50:673-678. (Pubitemid 44218660)
11. Benchenane K, Castel H, Boulouard M, Bluthé R, Fernandez-Monreal M, Roussel BD, et al. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci. 2007;120:578-585. (Pubitemid 46437892)
12. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
13. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-397. (Pubitemid 29453643)
14. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology. 1999;38:735-767. (Pubitemid 29187336)
15. Macrez R, Obiang P, Gauberti M, Roussel BD, Baron A, Parcq J, et al. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke. 2011;42: 2315-2322.
16. Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol. 1992;215:265-269.
17. Lapchak PA. Memantine, an uncompetitive low affinity NMDA openchannel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res. 2006;1088:141-147. (Pubitemid 44250968)
18. Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs. 2007;12: 389-406. (Pubitemid 47518375)
19. Kotermanski SE, Johnson JW. Mg2-imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci. 2009;29: 2774-2779.
20. Baron A, Montagne A, Cassé F, Launay S, Maubert E, Ali C, et al. NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ. 2010;17: 860-871.
21. Jullienne A, Montagne A, Orset C, Lesept F, Jane DE, Monaghan DT, et al. Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo. Mol Neurodegener. 2011;6:68.
22. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke. 2007;38:2771-2778. (Pubitemid 47494017)
23. Rosenberg GA, Mun-Bryce S, Wesley M, Kornfeld M. Collagenaseinduced intracerebral hemorrhage in rats. Stroke. 1990;21:801-807.
24. Culmsee C, Junker V, Kremers W, Thal S, Plesnila N, Krieglstein J. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke. 2004;35:1197-1202. (Pubitemid 38543543)
25. Vandeputte C, Taymans J, Casteels C, Coun F, Ni Y, Van Laere K, et al. Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci. 2010;11:92.
26. Lipton SA, Chen HV. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 2004;11:18-20. (Pubitemid 38111368)
27. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol. 2003;2:503-505. (Pubitemid 36876107)
28. Block F, Schwarz M. Memantine reduces functional and morphological consequences induced by global ischemia in rats. Neurosci Lett. 1996; 208:41-44. (Pubitemid 26130443)
29. García-Yébenes I, Sobrado M, Zarruk JG, Castellanos M, Pérez de la Ossa N, Dávalos A, et al. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke. 2011;42:196-203.
30. Back T, Otto D, Kittner D, Schüler OG, Hennerici MG, Mennel HD. Failure to improve the effect of thrombolysis by memantine in a rat embolic stroke model. Neurol Res. 2007;29:264-269. (Pubitemid 46802363)
31. Dogan A, Eras MA, Rao VL, Dempsey RJ. Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Acta Neurochir (Wien). 1999;141:1107:1113.
32. Marvanová M, Lakso M, Pirhonen J, Nawa H, Wong G, Castrén E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci. 2001;18:247-258. (Pubitemid 33027930)
33. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;2:CD003154.
34. Sinn D, Lee S, Chu K, Jung KH, Song EC, Kim JM, et al. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett. 2007;411:238-242. (Pubitemid 44828283)
35. Lee S, Chu K, Jung K, Kim J, Kim EH, Kim SJ, et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab. 2006;26: 536-544.
36. Thiex R, Weis J, Krings T, Barreiro S, Yakisikli-Alemi F, Gilsbach JM, et al. Addition of intravenous N-methyl-D-aspartate receptor antagonists to local fibrinolytic therapy for the optimal treatment of experimental intracerebral hemorrhages. J Neurosurg. 2007;106:314-320. (Pubitemid 46203161)
37. Berthier ML, Green C, Lara JP, Higueras C, Barbancho MA, Dávila G, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65:577-585.